15 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 15 of 15 clinical reviews.
A clinician-reviewed guide to transitioning adolescent patients (ages 12-17) from pediatric to adult care while managing bremelanotide (Vyleesi) therapy, including FDA labeling considerations, safety data, and practical handoff frameworks.
A clinician-reviewed guide covering how bremelanotide (Vyleesi) affects school attendance, physical activity, driving, and daily scheduling in adolescents aged 12 to 17, with dosing details, side-effect timelines, and practical management strategies.
A clinician-reviewed deep-dive into why Vyleesi (bremelanotide) is not approved for adolescents ages 12 to 17, what the developmental safety concerns are, and what evidence-based alternatives exist for hypoactive sexual desire disorder in younger populations.
A clinician-reviewed deep-dive into bremelanotide (Vyleesi) off-label use in adolescents aged 12 to 17, covering FDA approval status, pharmacology, safety data, and clinical guidance for prescribers and patients.
A clinician-reviewed guide to off-label bremelanotide use in patients 65+, covering pharmacokinetics, cardiovascular risk, dosing considerations, and what the evidence actually shows for older women with HSDD.
A clinician-reviewed guide to bremelanotide (Vyleesi) use in patients 65 and older, covering pharmacokinetics, safety signals, dose adjustments, cardiovascular precautions, and transition-of-care planning for geriatric patients with hypoactive sexual desire disorder.
A physician-reviewed deep dive into the geriatric use of bremelanotide (Vyleesi), pharmacokinetics, safety signals, clinical trial data, and prescribing guidance for adults 65 and older.
Vyleesi (bremelanotide) is FDA-approved only for premenopausal adult women. No pediatric dose, safety data, or administration protocol exists for children under 12. Learn what caregivers must know.
A clinical review of bremelanotide (Vyleesi) in pediatric patients under age 12, covering developmental safety, FDA labeling, melanocortin receptor biology, and why this drug has no role in prepubertal children.
A thorough clinical review of bremelanotide (Vyleesi) use in pediatric patients under age 12, covering FDA approval status, off-label considerations, safety data, and prescribing guidance from HealthRX's medical team.
Bremelanotide (Vyleesi) is FDA-approved only for premenopausal adults. This clinical guide explains why it has no established role in pediatric patients under 12, what parents and clinicians should know about safety, and how to approach school and activity planning when a household member uses it.
Bremelanotide (Vyleesi) is FDA-approved only for premenopausal adults. This clinical guide explains why pediatric use is contraindicated, what happens at age 18, and how providers should manage transition to adult sexual-health care.
A clinician-reviewed guide for caregivers administering bremelanotide (Vyleesi) to adolescents aged 12 to 17, covering injection technique, timing, safety monitoring, and FDA-approved use parameters.
A complete clinical guide to administering bremelanotide (Vyleesi) in patients aged 65 and older, covering pharmacokinetics, dose timing, caregiver injection technique, contraindications, and monitoring protocols reviewed by the HealthRX medical team.
A clinical guide to bremelanotide (Vyleesi) use in adults aged 65 and older, covering pharmacokinetics, activity restrictions, fall risk, cardiovascular precautions, and how to counsel older patients on safe daily functioning.